Aziyo Biologics Reports Second Quarter 2023 Financial Results - Transformation Continues to Drug-Eluting Biomatrix Company
Provided By GlobeNewswire
Last update: Aug 14, 2023
Negotiating multiple LOIs to divest Orthopedic business
CanGaroo® RM 510(k) resubmission to the FDA remains on track
SimpliDerm® quarterly net sales up 32% year-over-year
Read more at globenewswire.com
